DOCSLIB.ORG

Fr29de08n Teva Pharmaceutical Industries Ltd. and Barr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fr29de08n Teva Pharmaceutical Industries Ltd. and Barr 79486 Federal Register / Vol. 73, No. 249 / Monday, December 29, 2008 / Notices The Commission therefore determines precautions. Comments that do not Analysis of Agreement Containing that the maximum allowable charge for contain any nonpublic information may Consent Order To Aid Public Comment the year 2009 will be $11.00. instead be filed in electronic form by The Federal Trade Commission By direction of the Commission. following the instructions on the web- (‘‘Commission’’) has accepted, subject to Donald S. Clark, based form at (http:// final approval, an Agreement secure.commentworks.com/ftc- Secretary. Containing Consent Orders (‘‘Consent TevaBarr). To ensure that the Agreement’’) from Teva Pharmaceutical [FR Doc. E8–30830 Filed 12–24–08: 8:45 am] Commission considers an electronic BILLING CODE 6750–01–S Industries Ltd. (‘‘Teva’’) and Barr comment, you must file it on that web- Pharmaceuticals Inc. (‘‘Barr’’) that is based form. designed to remedy the anticompetitive The FTC Act and other laws the FEDERAL TRADE COMMISSION effects of the acquisition of Barr by Commission administers permit the Teva. Under the terms of the proposed [File No. 081 0224] collection of public comments to Consent Agreement, the companies consider and use in this proceeding as Teva Pharmaceutical Industries Ltd. would be required to assign and divest appropriate. All timely and responsive to Watson Pharmaceuticals (‘‘Watson’’) and Barr Pharmaceuticals, Inc; public comments, whether filed in Analysis of Agreement Containing Teva’s rights and assets necessary to paper or electronic form, will be manufacture and market generic: (1) Consent Orders To Aid Public considered by the Commission, and will Comment chlorzoxazone tablets; (2) deferoxamine be available to the public on the FTC injection; (3) fluoxetine weekly website, to the extent practicable, at AGENCY: Federal Trade Commission. capsules; (4) carboplatin injection; and www.ftc.gov. As a matter of discretion, ACTION: Proposed Consent Agreement. (5) metronidazole tablets. The Consent the FTC makes every effort to remove Agreement also requires the companies SUMMARY: The consent agreement in this home contact information for to assign and divest to Watson all of matter settles alleged violations of individuals from the public comments it Barr’s rights and assets necessary to federal law prohibiting unfair or receives before placing those comments manufacture and market generic: (1) deceptive acts or practices or unfair on the FTC website. More information, metoclopramide hydrochloride (‘‘HCl’’) methods of competition. The attached including routine uses permitted by the tablets; (2) cyclosporine liquid; (3) Analysis to Aid Public Comment Privacy Act, may be found in the FTC’s cyclosporine capsules; (4) desmopressin describes both the allegations in the privacy policy, at (http://www.ftc.gov/ acetate tablets; (5) epoprostenol sodium draft complaint and the terms of the ftc/privacy.shtm). (freeze-dried powder) injection consent order—embodied in the consent FOR FURTHER INFORMATION CONTACT: (‘‘epop’’); (6) flutamide capsules; (7) agreement—that would settle these Stephanie C. Bovee, FTC Bureau of glipizide/metformin HCl tablets; (8) allegations. Competition, 600 Pennsylvania Avenue, mirtazapine orally disintegrating tablets NW, Washington, D.C. 20580, (202) 326- DATES: (‘‘ODT’’); (9) tamoxifen citrate tablets; Comments must be received on 2083. or before January 19, 2008 and (10) tetracycline HCl capsules. In SUPPLEMENTARY INFORMATION: Pursuant addition, the proposed Consent ADDRESSES: Interested parties are to section 6(f) of the Federal Trade Agreement requires the companies to invited to submit written comments. Commission Act, 38 Stat. 721, 15 U.S.C. divest Teva’s rights and assets necessary Comments should refer to ‘‘Teva-Barr, 46(f), and § 2.34 of the Commission to manufacture and market generic File No. 081 0224,’’ to facilitate the Rules of Practice, 16 CFR 2.34, notice is trazodone HCl tablets and thirteen oral organization of comments. A comment hereby given that the above-captioned contraceptive products to Qualitest filed in paper form should include this consent agreement containing a consent Pharmaceuticals (‘‘Qualitest’’). reference both in the text and on the order to cease and desist, having been The proposed Consent Agreement has envelope, and should be mailed or filed with and accepted, subject to final been placed on the public record for delivered to the following address: approval, by the Commission, has been thirty days for receipt of comments by Federal Trade Commission/Office of the placed on the public record for a period interested persons. Comments received Secretary, Room 135-H, 600 of thirty (30) days. The following during this period will become part of Pennsylvania Avenue, N.W., Analysis to Aid Public Comment the public record. After thirty days, the Washington, D.C. 20580. Comments describes the terms of the consent Commission will again review the containing confidential material must be agreement, and the allegations in the proposed Consent Agreement and the filed in paper form, must be clearly complaint. An electronic copy of the comments received, and will decide labeled ‘‘Confidential,’’ and must full text of the consent agreement whether it should withdraw from the comply with Commission Rule 4.9(c). 1 package can be obtained from the FTC proposed Consent Agreement, modify it, 16 CFR 4.9(c) (2005). The FTC is Home Page (for December 19, 2008), on or make final the Decision and Order requesting that any comment filed in the World Wide Web, at (http:// (‘‘Order’’). paper form be sent by courier or www.ftc.gov/os/2008/12/index.htm). A Pursuant to an Agreement and Plan of overnight service, if possible, because paper copy can be obtained from the Merger dated July 18, 2008, Teva U.S. postal mail in the Washington area FTC Public Reference Room, Room 130- proposes to acquire all of the issued and and at the Commission is subject to H, 600 Pennsylvania Avenue, NW, outstanding shares of Barr for delay due to heightened security Washington, D.C. 20580, either in approximately $7.4 billion, plus the person or by calling (202) 326-2222. assumption of $1.5 billion of net debt, 1 The comment must be accompanied by an explicit request for confidential treatment, Public comments are invited, and may for approximately $8.9 billion. The including the factual and legal basis for the request, be filed with the Commission in either Commission’s Complaint alleges that and must identify the specific portions of the paper or electronic form. All comments the proposed acquisition, if comment to be withheld from the public record. should be filed as prescribed in the consummated, would violate Section 7 The request will be granted or denied by the ADDRESSES Commission’s General Counsel, consistent with section above, and must be of the Clayton Act, as amended, 15 applicable law and the public interest. See received on or before the date specified U.S.C. § 18, and Section 5 of the Federal Commission Rule 4.9(c), 16 CFR 4.9(c). in the DATES section. Trade Commission Act, as amended, 15 VerDate Aug<31>2005 15:57 Dec 24, 2008 Jkt 217001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\29DEN1.SGM 29DEN1 dwashington3 on PROD1PC60 with NOTICES Federal Register / Vol. 73, No. 249 / Monday, December 29, 2008 / Notices 79487 U.S.C. § 45, by lessening competition in proposed acquisition reduces the generic metronidazole, resulting in a the U.S. markets for the manufacture number of competitors from three to combined market share of 89 percent. and sale of the following generic two. Tamoxifen citrate is a selective ∑ Trazodone is an antidepressant with pharmaceutical products: (1) estrogen receptor modulator that is used a sedative effect. In the generic tetracycline HCl capsules; (2) in the treatment of breast cancer. trazodone market, the proposed chlorzoxazone tablets; (3) desmopressin Cyclosporine is an immunosuppressant acquisition would result in a acetate tablets; (4) metoclopramide HCl drug used to prevent the rejection of combined market share of 75 percent. tablets; (5) carboplatin injection; (6) transplanted organs. Combined, Teva Apotex Group is the only other tamoxifen citrate tablets; (7) and Barr, currently account for 73 competitively significant supplier metronidazole tablets; (8) trazodone HCl percent of the generic tamoxifen citrate with 22 percent of the market. The tablets; (9) glipizide/metformin HCl market and 55 percent of the generic fourth supplier—Watson—has had tablets; (10) cyclosporine liquid; (11) cyclosporine liquid market. limited success in this market, having cyclosporine capsules; (12) flutamide Teva’s proposed acquisition of Barr captured only a 3 percent market capsules; (13) mirtazapine ODT; (14) share to date. would reduce the number of ∑ deferoxamine injection; (15) epop; (16) competitors from four to three in the Cyclosporine is an weekly fluoxetine capsules; and (17) following generic markets: (1) immunosuppressant drug used to thirteen generic oral contraceptive metoclopramide HCl tablets; (2) prevent the rejection of transplanted markets (collectively, the ‘‘Products’’). carboplatin injection; (3) metronidazole organs. In the generic cyclosprine The proposed Consent Agreement will tablets; (4) trazodone HCl tablets; (5) capsules market, Teva and Barr have remedy the alleged violations by cyclosporine capsules; (6) flutamide roughly equal market shares and their replacing the lost competition that capsules; (7) glipizide/metformin HCl post-acquisition
Load more

Recommended publications
  • Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines
    Amgen 2008 Annual Report and Financial Summary Pioneering science delivers vital medicines About Amgen Products Amgen discovers, develops, manufactures Aranesp® (darbepoetin alfa) and delivers innovative human therapeutics. ® A biotechnology pioneer since 1980, Amgen Enbrel (etanercept) was one of the fi rst companies to realize ® the new science’s promise by bringing EPOGEN (Epoetin alfa) safe and effective medicines from the lab Neulasta® (pegfi lgrastim) to the manufacturing plant to patients. NEUPOGEN® (Filgrastim) Amgen therapeutics have changed the practice of medicine, helping millions of Nplate® (romiplostim) people around the world in the fi ght against ® cancer, kidney disease, rheumatoid Sensipar (cinacalcet) arthritis and other serious illnesses, and so Vectibix® (panitumumab) far, more than 15 million patients worldwide have been treated with Amgen products. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. 0405 06 07 08 0405 06 07 08 0405 06 07 08 0405 06 07 08 Total revenues “Adjusted” earnings Cash fl ow from “Adjusted” research and ($ in millions) per share (EPS)* operations development (R&D) expenses* (Diluted) ($ in millions) ($ in millions) 2008 $15,003 2008 $4.55 2008 $5,988 2008 $2,910 2007 14,771 2007 4.29 2007 5,401 2007 3,064 2006 14,268 2006 3.90 2006 5,389 2006 3,191 2005 12,430 2005 3.20 2005 4,911 2005 2,302 2004 10,550 2004 2.40 2004 3,697 2004 1,996 * “ Adjusted” EPS and “adjusted” R&D expenses are non-GAAP fi nancial measures. See page 8 for reconciliations of these non-GAAP fi nancial measures to U.S.
    [Show full text]
  • AILERON THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 AILERON THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents AILERON THERAPEUTICS, INC.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Form
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the fiscal year ended December 31, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 Commission file number 000-12477 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Amgen Center Drive, 91320-1799 Thousand Oaks, California (Zip Code) (Address of principal executive offices) (805) 447-1000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.0001 par value; preferred share purchase rights (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Reporte Anual
    Clave de Cotización: ORBIA Fecha: 2019-12-31 [411000-AR] Datos generales - Reporte Anual Reporte Anual: Anexo N Oferta pública restringida: No Tipo de instrumento: Acciones,Deuda LP Emisora extranjera: No Mencionar si cuenta o no con aval u otra garantía, La emisión de Certificados Bursátiles se encuentra especificar la Razón o Denominación Social: avalada por las subsidiarias de la Compañía denominadas Mexichem Compuestos, S.A. de C.V., Mexichem Amanco Holding, S.A. de C.V., Mexichem Derivados, S.A. de C.V., Mexichem Resinas Vinílicas, S.A. de C.V., Mexichem Flúor, S.A. de C.V., y Mexichem Brasil Industria de Transformação Plástica Ltda. (“Mexichem Brasil”), esta última subsidiaria aval es una sociedad de nacionalidad brasileña y la totalidad de sus activos se encuentran ubicados fuera de México. De igual manera, en caso de insolvencia o quiebra de Mexichem Brasil, las reclamaciones de los Tenedores conforme a los Certificados Bursátiles quedarán sujetas a la preferencia que establezcan las leyes aplicables en la República Federal de Brasil. En su caso, detallar la dependencia parcial o total: No 1 de 209 Clave de Cotización: ORBIA Fecha: 2019-12-31 [412000-N] Portada reporte anual Orbia Advance Corporation, S.A.B. de C.V. Avenida Paseo de la Reforma 483, piso 47, Colonia Cuauhtémoc, Alcaldía Cuauhtémoc, Ciudad de México, 06500 Tel. 5366 4000 2 de 209 Clave de Cotización: ORBIA Fecha: 2019-12-31 Serie [Eje] I II Especificación de las características de los títulos en circulación [Sinopsis] Clase I II Serie Única Única Tipo Nominativa
    [Show full text]
  • Pharmaceutical Settlements
    Drug Patent Settlements Between Rivals: A Survey C. Scott Hemphill Columbia Law School Working paper available at ssrn.com/abstract=969492 March 12, 2007 Electronic copy of this paper is available at: http://ssrn.com/abstract=969492 Drug Patent Settlements Between Rivals: A Survey C. Scott Hemphill* Introduction .......................................................................................................................................... 3 I. Settlements in summary ........................................................................................................... 5 II. The mechanisms of payment for delay................................................................................. 13 A. Compensation to the generic firm............................................................................... 14 1. Cash and overpayment...................................................................................... 14 2. Preserving exclusivity........................................................................................ 16 3. Underpricing....................................................................................................... 18 4. Additional channels........................................................................................... 19 B. Delay in generic entry................................................................................................... 20 1. Neutralizing the first filer ................................................................................. 20 2. Bottleneck
    [Show full text]
  • Healthcare Conference
    25th Annual HEALTHCARE CONFERENCE Healthcare Westin St. Francis San Francisco January 8–11, 2007 JPMorgan cordially invites you to attend the 25th Annual Healthcare Conference, January 8 –11, 2007, at the Westin St. Francis in San Francisco. JPMorgan’s premier conference on the healthcare industry will feature more than 260 public and private companies over four days of simultaneous sessions. In addition, the conference will host topical panel discussions featuring leading industry experts. Preliminary List of Invited Presenting Companies Actelion Ltd Baxter International Inc. Cooper Companies Aetna Incorporated BD (Becton, Dickinson) Coventry Affymetrix, Inc. Beckman Coulter, Inc. Dade Behring Holdings, Inc. Alcon, Inc. Bioenvision, Inc. DaVita Inc. Align Technology, Inc. Biogen Idec deCODE genetics, Inc. Allscripts Healthcare Solutions Inc. Biomet, Inc. Digene Altana Boston Scientific Corporation Digirad Corporation — US American Medical Systems Holdings Inc. Bristol-Myers Squibb Company Diversa Corporation Amerigroup Corp. Cambrex Corporation DJO Incorporated AmerisourceBergen Cardinal Health, Inc. Dyax Corp. Amgen, Inc. Caremark Rx, Inc. Eclipsys Corporation AMN Healthcare Services, Inc. Celgene Corporation Edwards Lifesciences Corporation AmSurg Corporation Cell Genesys Elan Corporation, plc Anadys Pharmaceuticals CENTENE Corporation Eli Lilly and Company Applied Biosystems Group Cephalon, Inc. Emdeon Ariad Pharmaceuticals, Inc. Cerner Corporation Emergency Medical Services Corporation AstraZeneca Group plc Charles River Laboratories,
    [Show full text]
  • Inside This Issue
    Vol. 25, No. 21 Bayer, Generic Firms Win Oct. 29, 2008 In Antitrust Case INSIDE THIS ISSUE A federal appeals court has upheld a ruling that agreements be- tween Bayer and four generics firms on the antibiotic Cipro did not violate the Sherman Antitrust Act or state antitrust regulations or laws. Ask the Expert: Michelle Seagull comments on Cipro In its decision, the U.S. Court of Appeals for the Federal Cir- antitrust case............Page 3 cuit agreed with the In re Ciprofloxacin Hydrochloride Antitrust Litigation decision made by the U.S. District Court for the Eastern FDA: Agency seeks to District of New York in favor of Bayer, Hoechst Marion Roussel withdraw ANDAs for (HMR), Rugby Laboratories, Watson Pharmaceuticals and Barr MiraLax...................Page 5 Laboratories. Clinical Trial: UK OKs The appeals court found the companies did not engage in anti- INS-20 trial..............Page 5 competitive practices when they signed agreements with Bayer not Lawsuits: Mylan gets two (See Antitrust, Page 2) tentative approvals, faces Novartis suit ............Page 6 Court Finds Against Sandoz In Biaxin XL Case Industry News: Par to re- structure business ....Page 7 A federal appeals court upheld a preliminary injunction barring Sandoz from selling a generic version of Abbott Laboratories’ ex- Mergers/Acquisitions: tended-release antibiotic Biaxin. Stakeholder downplays Ac- tavis sale rumors......Page 7 The split decision by the U.S. Court of Appeals for the Federal Circuit moves the patent dispute back to the U.S. District Court for FTC: Court agrees to halt the Northern District of Illinois for further proceedings on the case, websites’ sale of unap- which started when Abbott sued Sandoz in 2005 for infringing on its proved drugs............Page 7 ’718, ’616 and ’407 patents on Biaxin (clarithromycin).
    [Show full text]
  • 1 4164-01-P Department of Health and Human Services
    This document is scheduled to be published in the Federal Register on 10/04/2016 and available online at https://federalregister.gov/d/2016-23893, and on FDsys.gov 1 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2016-N-0002] Hospira, Inc. et al.; Withdrawal of Approval of 44 New Drug Applications and 158 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 44 new drug applications (NDAs) and 158 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: Effective Date: [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) 2 is without prejudice to refiling. Table 1 Application No.
    [Show full text]
  • FOSAMAX (ALENDRONATE SODIUM) : MDL No
    Case 3:11-cv-03045-JAP-LHG Document 148 Filed 01/17/12 Page 1 of 6 PageID: <pageID> NOT FOR PUBLICATION ___________________________________________ : IN RE: FOSAMAX (ALENDRONATE SODIUM) : MDL No. 2243 PRODUCTS LIABILITY LITIGATION (NO. II) : (JAP-LHG) : : MEMORANDUM OPINION RELATES TO ALL ACTIONS : : PISANO, Judge Presently before the Court is Defendants’ Watson Pharmaceuticals, Inc. and Watson Laboratories, Inc. (collectively “Watson”) Motion for Judgment on the Pleadings seeking dismissal from this MDL pursuant to the Supreme Court’s decision in PLIVA v. Mensing, 131 S. Ct. 2567 (2011). (DE 250.) Plaintiffs opposed the motion. (DE 296.) On January 12, 2012, the Court held oral argument on Watson’s motion. For the reasons that follow, the Court will grant the motion and dismiss Watson from the case. I. BACKGROUND The MDL is a series of products liability suits concerning Fosamax, a drug prescribed for the treatment and prevention of osteoporosis and Paget’s disease. Plaintiffs in these cases brought claims in various courts and venues against both the manufacturer of Fosamax, Merck & Co., Inc. (“Merck”), and against manufacturers of generic Fosamax. Plaintiffs’ claims emanated from a general theory of failure to warn, but also included claims based upon various state law products liability theories, including, inter alia, defective design, negligence, fraud, misrepresentation, breach of express and implied warranties, violation of consumer protection statutes, restitution, and loss of consortium. On May 25, 2011, the United States Judicial Panel Case 3:11-cv-03045-JAP-LHG Document 148 Filed 01/17/12 Page 2 of 6 PageID: <pageID> on Multidistrict Litigation centralized all actions for coordinated and consolidated pretrial proceedings in the District of New Jersey.
    [Show full text]
  • Russia, Eastern Europe Growing on the Generics Scene
    April 17, 2008 Russia, Eastern Europe growing on the generics scene Amy Brown While dominance of the generics scene in terms of scale is set to remain in the hands of Teva, Novartis’s Sandoz and Mylan, and Indian firms have been making inroads for some time, companies emerging from Eastern Europe and Russia are increasingly moving up the rankings and featuring at the top of sales growth tables. EvaluatePharma’s Peer Group Analyzer shows that in terms of unbranded prescription sales growth over the next five years, Russian firms in particular are doing well at the top of the table, as spending on healthcare in the region grows (see table below). IMS recently reported that Russia was the fastest growing pharmaceutical market in the European region in 2007, expanding by 20%. Market WW Unbranded Generic Sales - ranked on growth rate Rank Compound Annual Sales in 2012 # Company Location Growth Rate 2007 2012 (US$m) (2007 to 2012) 1 Bioton Poland 51% 43 36 203 2 Veropharm Russia 32% 36 27 453 3 IMPAX Laboratories USA 24% 35 29 381 4 Mylan USA 21% 4 3 4,922 5 Pharmstandard Russia 21% 23 18 987 Glenmark 6 India 17% 25 19 823 Pharmaceuticals Czech 7 Zentiva 17% 18 15 1,354 Republic Sun Pharmaceutical 8 India 16% 19 16 1,243 Industries 9 Aurobindo Pharma India 15% 31 30 332 10 Matrix Laboratories India 15% 34 34 263 Top of the list is Poland’s Bioton, a small company which derives the majority of its sales from insulin and antibiotics.
    [Show full text]
  • Advanced Sterilization Products Alpharma Pharmaceuticals
    Manufacturers/Wholesalers Street City ST Zip Abbott Diabetes Care Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Abbott Nutrition Abbott Pharmaceutical Products Group Abbott Point of Care Abbott Spine Abbott Vascular Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Advanced Medical Optics, Inc. 1700 E. St. Andrew Place Santa Anna CA 92705 Advanced Neuromodulation Systems, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Agencourt Bioscience Corporation Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allergan American, LLC. Allergan Holdings, Inc, Allergan Puerto Rico Holdings, Inc. Allergan Sales Allergan Sales Puerto Rico, Inc. Allergan Specialty Therapeutics, Inc. Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Allscripts, LLC. 2401 Commerce Drive Libertyville IL 60048 Alpharma Pharmaceuticals, LLC 1 New England Ave Piscataway NJ 08854 American Medical System, Inc 10700 Bren Road West Minnetonka MN 55343 Ameridose, LLC. 50 Fountain Street Framingham MA 01702 Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 Amgen, USA AMO Sales and Service, Inc. Amphastar Pharmaceuticals, Inc. 11570 Sixth St. Rancho Cucamnga CA 91730 AMS- AMS Innovation Center 3070 Orchard Drive San Jose CA 95134 AMS Sales Corporation 10700 Bren Road West Minnetonka MN 55343 Amylin Pharmaceutical, Inc. 9360 Towne Center Drive San Diego CA 92121 Anda Pharmaceuticals, Inc.
    [Show full text]
  • Genetic Engineering
    GENETIC ENGINEERING A Reference Handbook Second Edition Other Titles in ABC-CLIO’s CONTEMPORARY WORLD ISSUES Series Cults, James R. Lewis Forest Fires, Philip N. Omi Gun Control in the United States, Gregg Lee Carter Hate Crimes, Donald Altschiller Human Rights Worldwide, Zehra F. Kabasakal Arat Hurricanes, Patrick J. Fitzpatrick Illicit Trafficking, Robert J. Kelly, Jess Maghan, Joseph DiSerio International Environmental Disputes, Aaron Schwabach Invasion of Privacy, Kevin M. Keenan Juvenile Justice, Donald J. Shoemaker and Timothy W. Wolfe Native American Issues, William N. Thompson New Slavery, Kevin Bales Punishment in America, Cyndi Banks U.S. Homeland Security, Howard Ball United Nations System, The, Chadwick F. Alger Violence in the Media, Nancy Signorielli Upcoming Titles Childhood Sexual Abuse, Karen L. Kinnear Conflicts over Natural Resources, Jacqueline Vaughn Illegal Immigration, Michael C. LeMay Internet and Society, The, Bernadette H. Schell U.S. Military Service, Cynthia A. Watson World Population, Geoffrey Gilbert Books in the Contemporary World Issues series address vital issues in today’s society such as genetic engineering, pollution, and biodiversity. Written by professional writers, scholars, and nonacademic experts, these books are authoritative, clearly written, up-to-date, and objective. They provide a good starting point for research by high school and college students, scholars, and general readers as well as by legislators, businesspeople, activists, and others. Each book, carefully organized and easy to use, contains an overview of the subject, a detailed chronology, biographical sketches, facts and data and/or documents and other primary- source material, a directory of organizations and agencies, an- notated lists of print and nonprint resources, and an index.
    [Show full text]